The SEC told Gilead Sciences Inc., of Foster City, Calif., and Vertex Pharmaceuticals Inc., of Cambridge, Mass., they could not block shareholders from voting on proposals asking for greater transparency around the management and mitigation of the business risks from rapidly increasing U.S. drug prices.